1. Introduction {#s0005}
===============

Atrial fibrillation (AF) is the most common cardiac arrhythmia affecting worldwide more than 30 million patients [@b0005], [@b0010]. AF is associated with an increased risk for stroke, heart failure and dementia, increased morbidity and mortality in affected patients and causes significant health costs [@b0005], [@b0010].

AF is a clinical condition which may progress from paroxysmal (duration \< 7 days, self-terminating), to persistent (duration \> 7 days, requires medical intervention for termination), and permanent AF (despite treatment no restoration of normal sinus rhythm or not treated) [@b0015]. The pathogenesis is multifactorial and includes risk factors like coronary artery disease, valvular heart disease, hypertension, heart failure, diabetes, sleep apnea, obesity, inflammation, and activation of the autonomic nervous system [@b0020].

Manifestation of electrical (e.g., ion channel dysfunction, conduction slowing) and structural (e.g., interstitial fibrosis, cellular hypertrophy, mitochondrial dysfunction) remodeling are key elements of the substrate that promotes the progression of AF to more persistent forms and contributes to the development of an atrial cardiomyopathy that supports the persistence of AF [@b0025], [@b0030], [@b0035], [@b0040], [@b0045].

1.1. Standard of care and unmet medical need for novel therapies {#s0010}
----------------------------------------------------------------

Current AF treatment comprises prevention of thromboembolism and stroke, risk factor management as well as antiarrhythmic therapy by drugs, electrical cardioversion, and catheter ablation [@b0050]. Effective long-term rhythm control improves quality of life and can reduce associated health risk factors. Despite recent advances in interventional ablation therapy [@b0055], antiarrhythmic drugs (AADs) remain the cornerstone treatment option for the majority of AF patients worldwide, although AADs are only moderately effective and possess substantial cardiac and non-cardiac toxicity. Thus, there is an unmet need for novel AADs with improved efficacy and safety profiles [@b0060]. The expected increase in AF prevalence with the aging of the population increases the pressure to develop improved AADs because invasive ablation procedures cannot be applied to this large patient population. In addition, the improvement of AF detection methods, e.g., the use of (insertable) cardiac monitors (ICMs) for continuous 24/7 surveillance of patients or emerging wearable, home-based AF sensors [@b0065], enhances continuously the understanding of the disease and calls for improvement of AADs available. Compared to the electrocardiogram (ECG)-based assessment of the AF phenotypes, continuous and long-term AF monitoring offers improved opportunities to define and quantify the real AF burden, the relationship of AF burden to cardiovascular and neurological outcomes, and the success rate of AF treatments [@b0070], [@b0075].

Currently marketed AADs follow the classic concepts of selective channel and multichannel block. However, low long-term efficacy and the risk of proarrhythmia along with non-cardiac adverse events are relevant disadvantages limiting the clinical benefit for AF patients [@b0080], [@b0085], [@b0090]. Conceptually, novel AADs should target the multifactorial pathogenesis of AF and ideally prevent the development and halt the progression of the AF-promoting atrial cardiomyopathy. Several molecular mechanisms contributing to AF-promoting electrical and structural remodeling have been identified as potential molecular targets for novel therapeutic approaches [@b0095] including alterations in intracellular Ca^2+^-handling [@b0045], [@b0100], [@b0105], mitochondrial dysfunction [@b0110], oxidative stress [@b0115], and inflammatory signaling [@b0120], [@b0125]. A new paradigm in the pharmacotherapy treatment of AF should consider the patients' individual arrhythmia mechanism and co-morbidities with the aim to increase both therapeutic efficacy and safety [@b0130].

1.2. OMT-28 to reinforce endogenous mechanisms of cardioprotection and antiarrhythmia {#s0015}
-------------------------------------------------------------------------------------

OMT-28 is a metabolically robust synthetic analog of 17,18-epoxyeicosatetraenoic acid (17,18-EEQ) and has been developed to mimic the antiarrhythmic and cardioprotective mechanisms of endogenous omega-3 epoxyeicosanoids [@b0135]. Omega-3 epoxyeicosanoids are bioactive lipid mediators generated by cytochrome P450 (CYP) enzymes from long-chain omega-3 polyunsaturated fatty acids (PUFAs), such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). 17,18-EEQ is the main product of EPA metabolism as catalyzed by CYP2J2, the major CYP epoxygenase in the human heart [@b0140]. Upon dietary EPA/DHA supplementation, 17,18-EEQ is the predominant epoxyeicosanoid both in rodents [@b0140] and humans [@b0145].

Omega-3 epoxyeicosanoids protect cardiomyocytes against Ca^2+^ overload [@b0140], inflammatory injury [@b0150], and hypoxia/reoxygenation-induced loss of cell viability and mitochondrial function [@b0155]. Most recently, the cardioprotective effect of omega-3 epoxyeicosanoids was shown to involve inhibition of inflammatory signaling [@b0160]. There is also evidence from animal studies indicating that reinforcing the CYP epoxygenase pathway has the potential to protect against cardiac remodeling and arrhythmia [@b0165], [@b0170]. In line with this notion, transgenic overexpression of CYP2J2 [@b0175], as well as inhibition of soluble epoxide hydrolase-mediated epoxyeicosanoid degradation [@b0180], was shown to reduce ventricular tachyarrhythmia and AF vulnerability in mice.

OMT-28 shares the cardioprotective and antiarrhythmic properties with its natural counterparts. Omega-3 epoxyeicosanoids and OMT-28 act via a putative G~αi~ protein-coupled receptor, which elicits PI3K/Akt/eNOS/PKG signaling as well as activation of sirtuin-1 and PPARα in cardiomyocytes. The net effect of this pathway consists in modulation of Ca^2+^-cycling, reduced electrical excitability, and protection against mitochondrial dysfunction and inflammatory injury ([Fig. 1](#f0005){ref-type="fig"}). This multimodal mode of action differentiates OMT-28 from the classical ion channel-inhibiting AADs and has the potential to simultaneously target several of the key mechanisms contributing to the evolution of the AF-promoting atrial substrate and an arrhythmia-related cardiomyopathy of the ventricles.Fig. 1Putative mechanisms of antiarrhythmic actions of OMT-28.

1.3. OMT-28 -- results of the phase I study {#s0020}
-------------------------------------------

OMT-28 was developed as an orally active compound. In an already completed phase I study in 76 healthy volunteers (NCT03078738), OMT-28 was proven to be safe and well tolerated in single and multiple ascending oral doses up to 60 mg once daily for up to 14 days. OMT-28 had no detectable effect on the normal values of investigated safety laboratory parameters, as well as heart rate and blood pressure. Notably, high-resolution ECGs excluded any exposure-related increase in the QTc interval. The compound reached steady-state within 14 days of once-daily dosing and showed high oral bioavailability and favorable pharmacokinetics with a fast uptake into the plasma (t~max~ of 1.25--2.0 h, median) and a plasma half-life (t~1/2~) of 65.8--85.9 h (median), validating its suitability for oral, once daily application.

2. Methods {#s0025}
==========

2.1. PROMISE-AF study design \[ClinicalTrials.gov Identifier: NCT03906799\] {#s0030}
---------------------------------------------------------------------------

We designed a placebo-controlled, double-blind, randomized, dose-finding, multicenter phase II study in patients with persistent AF for \> 7 days but ≤ 3 months who are suitable for direct current cardioversion (DCC) ([Fig. 2](#f0010){ref-type="fig"}). This study evaluates the efficacy, safety, and population pharmacokinetic (popPK) of three different doses of OMT-28 given once daily versus placebo in patients with persistent AF in maintaining sinus rhythm after DCC.Fig. 2Phase II study design and flowchart.

This study will be conducted in compliance with the protocol, the ethical principles as outlined in the Declaration of Helsinki, the International Conference on Harmonization (ICH) consolidated Guideline E6 for Good Clinical Practice (CPMP/ICH/135/95), and applicable regulatory requirement(s).

### 2.1.1. Study population {#s0035}

This study will enroll patients with documented AF for \> 7 days but ≤ 3 months that are eligible for DCC and anticoagulant therapy. Patients with prior or ongoing anticoagulant and/or single antiplatelet therapy are eligible as well as treatment-naïve patients. In contrast, patients with dual antiplatelet therapy are excluded because therapy also in combination with anticoagulants (i.e., triple therapy) is known to be associated with an increased risk of bleeding [@b0185], [@b0190], [@b0195], [@b0200]. Patients that have undergone surgical or catheter ablation for AF or atrial flutter are not allowed to participate in the study. However, patients with medical history of atrial flutter were not excluded because it is a common finding in AF patients and recruitment was not to be jeopardized. Nonetheless, special attention will be paid to these patients, i.e., information on incidence and duration of atrial flutter will be recorded as exploratory endpoint. Detailed inclusion and exclusion criteria are shown in Supplemental Table 1.

### 2.1.2. Study medication {#s0040}

OMT-28 will be administered orally in form of microcrystalline cellulose and anhydrous silica containing capsules of three different strengths. OMT-28 will be tested against placebo in patients receiving standard of care therapy, including anticoagulant or rate control therapy (e.g., Ca^2+^-channel blocker, β-blocker). Patients taking antiarrhythmic agents including dronedarone, oral amiodarone, or omega-3 fatty acids will not be included -- exclusion criteria 15 and 16. If during the study, the use of above-mentioned agents is deemed necessary by the investigator, the patient must be withdrawn from the study. The first dose of study drug is administered during Visit 3 under the supervision of the investigator. The study drug is labelled according to the ICH-GCP Guideline E6 (European Commission2/3/2010).

### 2.1.3. Study objectives & endpoints {#s0045}

The primary objective of the study is to assess the efficacy of three different doses of OMT-28 administered once daily versus placebo in the maintenance of normal sinus rhythm after electrical DCC in patients with persistent AF treated with an appropriate anticoagulant therapy.

The secondary objective of the study is the assessment of (i) the safety of three different doses of OMT-28 administered once daily versus placebo after DCC in patients with persistent AF and (ii) the PK of OMT-28 by means of popPK analysis.

All primary, secondary, and exploratory study endpoints on efficacy (incl. biomarker analysis) and safety are summarized in [Table 1](#t0005){ref-type="table"}.Table 1Primary, secondary, and exploratory efficacy and safety endpoints.Endpoints**Primary Efficacy Endpoint**•AF burden (% time with any AF after direct current cardioversion, DCC). This is defined as the area under the curve for daily estimates (Day 8-Day 99). In case of repeated DCC, the burden for the day of DCC and all following days will be estimated as the median of burden from onset of the current AF episode until DCC.**Secondary Efficacy Endpoints**•Recurrence rate (RecR) of persistent AF (defined as AF burden ≥ 23/24 h over 7 consecutive days) in at least one 7-day period•Time-to-recurrence (TTR) defined as days from the successful cardioversion to first documented recurrence (TTR) of persistent AF (defined as AF burden ≥ 23/24 h over 7 consecutive days) in at least one 7-day period**Exploratory Efficacy Endpoints**•RecR of non-persistent AF (defined as at least one AF episode not fulfilling the persistent AF definition)•TTR of non-persistent AF (defined as at least one AF episode not fulfilling the persistent AF definition)•AF burden during the first week of study drug intake prior to cardioversion•AF burden during the first week of study drug intake prior to cardioversion compared to baseline•AF burden after DCC compared to baseline•Incidence of conversion to sinus rhythm during the first week of study drug intake prior to cardioversion•Incidence of DCC procedures after successful DCC on Visit 4•Incidence and duration of atrial flutter/atrial tachycardia•Data collected from the patient diaries**Safety Endpoints**•Incidence, severity, seriousness, and treatment-causality of AEs•Clinically significant changes in safety laboratory evaluations, vital signs, 12 lead ECGs, ICM data, and physical examinations**Pharmacokinetic and Exploratory Pharmacodynamic Endpoints**•Pharmacokinetic (evaluated by means of popPK analysis)oPlasma concentration of OMT-28 and metabolitesoTrough plasma concentration (C~trough~)•Pharmacodynamic biomarker at baseline (Visit 3, Day 1) and at steady state (Visit 8, Day 99)oSerum biomarkers (GDF-15, Galectin-3, NT-proANP, NT-proBNP)oMetabolic biomarker (HbA1c, serum lipids)

#### 2.1.3.1. Key measurement -- insertable cardiac monitor {#s0050}

All patients will undergo ICM insertion during randomization at Visit 2. The trigger of the ICM from BIOTRONIK, BioMonitor 2-AF, will be programmed to detect the following arrhythmic events: AF, asystole, bradycardia, and high ventricular rate. The confirmation time for an AF episode is set from 6 min (standard settings) to 2 min. Further details on the study-specific programming are listed in Supplemental Table 2. Furthermore, patients will be equipped with the Remote Assistant, a device that can be used by the patient to trigger ICM recording in case of any symptoms.

Data recorded by the ICM will be transferred into the BIOTRONIK Home Monitoring® Service Center and finally into the software inSuite Cardio (Doc Cirrus), the latter allowing transfer of the data to the independent ICM Data Review Committee (ICM-DRC), comprising of qualified cardiologists who are not investigators in the study and not otherwise directly associated with the study sponsor, responsible for the evaluation of recorded episodes. The members of the committee will remain blinded to treatment throughout the evaluation process and the study. Evaluated data will be used in the final efficacy and safety analyses.

#### 2.1.3.2. Pharmacokinetics {#s0055}

A popPK analysis will be performed to gain relevant PK information in patients who are representative of the target population. There will be two study visits -- at the beginning of treatment and at steady state (Visit 3, Day 1 and Visit 6, Day 43 ± 3) -- with one pre-dose and three post-dose blood sampling procedures (within 15--45 min post dose, 1--2 h post dose, and 2.5--8 h post-dose). At Visit 4, 5, 7, 8, and 9 there will be one pre-dose sample only.

#### 2.1.3.3. Pharmacodynamics {#s0060}

Blood samples for PD assessment will be taken pre-dose at Visit 3, Day 1 and at steady state at Visit 8, Day 99. PD biomarker analysis includes the analysis of different cytokines, fatty acid profile in erythrocytes, or the endogenous CYP eicosanoid profile. Further PD analysis will be performed on proteins that are biologically related to (i) persistent AF and its progression and (ii) the known mode of action of OMT-28 and are, therefore, likely involved in further pharmacological effects. This includes biomarkers of oxidative stress, inflammation, and remodeling like growth differentiation factor 15 (GDF15), Interleukin-6 (IL-6), transforming growth factor beta-1 (TGF-β1), N-terminal pro-A/B-type natriuretic peptide (NT-proANP/NT-proBNP), tissue inhibitors of metalloproteinases metallopeptidase inhibitor 1 (TIMP-1), matrix metallopeptidase 9 (MMP-9), Galectin-3, glycated hemoglobin (HbA1c), and high-sensitivity troponin I. Measurement of C-reactive protein (CRP), total cholesterol, triglycerides, low density lipoprotein (LDL), high-density lipoprotein (HDL) and very low-density lipoprotein (VLDL) will allow to assess OMT-28-related changes in inflammation and lipid metabolism.

### 2.1.4. Study visit schedule {#s0065}

#### 2.1.4.1. Overview {#s0070}

Patients will be screened for eligibility during the screening period (within 22 days prior to dosing) ([Fig. 2](#f0010){ref-type="fig"}). At latest at randomization (Visit 2), the duration of the current episode of persistent AF must be shown to be \> 7 days but ≤ 3 months, as confirmed by two ECGs (one ECG must be a 12-lead ECG).

Patients will be randomized, stratified by sex in order to avoid gender-related exposure differences, in a 1:1:1:1-ratio to receive once-daily OMT-28 at a dose of 4, 12, or 24 mg or placebo. The following controls will be employed to maintain the double-blind status of the study: (i) placebo capsules will be identical in appearance to the OMT-28 capsules, (ii) investigator(s) and other members of staff involved with the study will remain blinded to the treatment randomization code during the assembly procedure, and (iii) all data will be provided to the Contract Research Organization in a blinded manner. Therefore, an Interactive Web Response System (IWRS) is implemented in the study and study medication bottles will be delivered automatically in a blinded fashion. Whenever necessary, in the opinion of the investigator, the study blind may be broken, and the patient will be withdrawn from the study. Date, time, and reason of the decision will be recorded in the patient's source data.

At the same visit, Visit 2, patients will receive the ICM device, which will be inserted subcutaneously under local anesthesia according to local treatment guidelines.

Eligible patients with proven persistent AF must have received adequate anticoagulant therapy for at least three weeks prior to first administration of study drug (OMT-28 or placebo) on Visit 3. Patients will receive study drug for at least one week prior to DCC on Visit 4.

In total, each patient will be treated over a period of 99 days once daily with either placebo or one of three doses of OMT-28. The definition for the treatment duration goes back to an extensive literature research, which showed that the timepoint of \~13 weeks is, for most AF post-DCC trials, predictive for the 6 months outcome. A comparable study (incl. placebo-control and post-DCC treatment) from De Ferrari et al. had only a slightly longer treatment duration of 16 weeks [@b0205]. The treatment phase is followed by an observation/follow-up phase of further 28 days ([Fig. 2](#f0010){ref-type="fig"}). No long-term follow-up is planned; however the patients are allowed to keep the ICM inserted.

Patients will be monitored for cardiac events throughout the study (Visit 2 to Visit 9) using the ICM. In addition, patients are requested to complete daily a patient diary to report subjectively perceived symptoms.

The study will include a sample size re-estimation analysis, when approximately 50% of the patients have completed the treatment phase (Visit 8).

#### 2.1.4.2. DCC {#s0075}

On Visit 4 (seven days after start of study drug administration), provided that anticoagulation is adequate in the preceding four weeks, patients remaining in AF, as confirmed by 12-lead ECG, will undergo DCC (performed according to the current local institutional practices). Patients will be allowed to receive more than one direct current shock if the first attempt failed to restore sinus rhythm. A 12-lead ECG will be performed 2 h after the DCC. Only patients with a successful cardioversion (i.e., who remain in sinus rhythm for at least 2 h after the DCC) will be included in the mITT population.

All patients (including those who do not remain in sinus rhythm for at least 2 h after the DCC) will continue to receive study drug and continue to be monitored throughout the remainder of the study. Patients who were not successfully cardioverted may be replaced.

### 2.1.5. Sample size calculation {#s0080}

The study aims to demonstrate that OMT-28 compared to placebo improves at least one of the three efficacy endpoints -- AF burden, recurrence rate (RecR), and time-to-recurrence (TTR) -- in the 3-months treatment period (Day 8-Day 99). AF burden is defined as % time with any AF after DCC. According to the set triggers all AF episodes \> 2 min duration are considered. RecR refers to persistent AF (defined as AF burden ≥ 23/24 h over 7 consecutive days) in at least one 7-day period. TTR is defined as the time (days) from the successful cardioversion to first documented recurrence of persistent AF in at least one 7-day period. Therapeutic effects of OMT-28 on RecR and/or TTR will be reflected in AF burden and no formal sample size estimation has been done for these measures. The probability of finding an expected predefined effect (statistical power) -- reflected in changes of AF burden -- is set to 80%. The probability of a false positive finding (significance level) is set to 5%. Statistical tests will be done with a predefined direction of difference, thus one-tailed significance level will be computed. An interim analysis will be performed if 50% of patients completed treatment phase (Visit 8). As such preliminary analysis increases the chance for false positive findings, the p-value will be adjusted for multiple testing. The O\'Brien Fleming methodology of splitting alpha will be used. P-threshold for the interim analyses will be 0.005574597, leading to a remaining p-threshold of 0.044425403 for the final analysis.

The estimated sample size is the number of patients per treatment group in the mITT population, as this is the primary population for evaluation of efficacy. Since published AF burden data in a post-DCC population from an interventional study with comparable design was not available, sample size was estimated based on simulations with parameters set according to published results [@b0210]. As base population, a random sample from a beta-distribution with shape parameters of 0.55 and 1 was drawn with 100,000 patients. From these data, a sub-population was filtered with AF burden between 2% and 95%. This population reflects the expected baseline values in the study population. From this population, 1000 samples per sample size were drawn and tested for significance. The RecR of placebo was set to 50, 60, 70, 80, or 85%. The effect size of verum compared to placebo (ΔRecR) was set - for each individual RecR placebo setting separately - to ±0, −5, −10, −20, and −30% to reflect a broad range of scenarios (e.g., RecR placebo 70%: RecR verum 70, 65, 60, 50, and 40%). As most realistic scenario, the RecR for placebo was set to 50%; the RecR for all treatment groups (verum) was set to 30%. Reduction in AF burden is the expected mean reduction of AF burden in patients with recurring AF. Atrial fibrillation burden reduction was set to 60%. This is a conservative estimate for the reduction of AF burden in the study as the "0″ for non-recurring AF will be included in the computation from study data. 1000 samples were simulated with affected/unaffected subjects according to RecR for placebo/verum and affected subjects with 60% reduced burden in simulated AF burden for verum only. For each simulation run, placebo vs. verum were compared by non-parametric tests, the rate of significant results over all simulations determined empirical power. Under these assumptions, 30 patients per study arm will give the desired statistical power. An interim analysis for sample size re-estimation will be performed once approximately 15 patients per study arm have completed the treatment phase (Visit 8) of the study to avoid an underpowered study because of imprecise estimates for study population or overoptimistic parameter estimates.

### 2.1.6. Study conduct & organization {#s0085}

#### 2.1.6.1. Study conduct {#s0090}

For the purpose of study conduct, 25 study sites in 4 different countries (Bulgaria, Czech Republic, Hungary, and Ukraine) were initiated. The recruitment of the study started in March 2019 and is expected to be completed within 9 months.

#### 2.1.6.2. Study organization {#s0095}

All investigators, sub-investigators, study coordinators and other involved site staff are obliged to comply with the study specifications.

An independent Data Monitoring Committee (DMC) is responsible for ensuring the safety and well-being of study patients, study integrity, and validity of study results by reviewing safety and efficacy data. Based on ongoing study data, the DMC is expected to make recommendations concerning study continuation, modification, and termination, if needed.

A quality control was implemented by installation of the independent, study-specific ICM-DRC, which will review recorded ECGs (≤6 per day per patient) in a blinded way and comment on the recorded episodes (true/false/not evaluable). Evaluated data will be considered for the final efficacy and safety analyses.

The study is funded by OMEICOS Therapeutics GmbH. The authors are solely responsible for the design and conduct of the study as well as drafting and editing of the manuscript, and its final contents.

3. Conclusions {#s0100}
==============

In summary, PROMISE-AF is a clinical phase II a/b dose-finding study evaluating three doses of OMT-28 compared to placebo in patients undergoing planned electrical cardioversion for persistent AF. The use of an ICM in all patients will allow to calculate the AF burden and other standard AF efficacy endpoints based on continuous monitoring and thus provide an extensive data set for the analysis and interpretation of the study results as a guidance for further clinical development of OMT-28.
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